A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Clinical trial NCT04876092 · COMPLETED

Trial details

NCT number: NCT04876092
Sponsor: Janssen Research & Development, LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin

Start date: 2021-07-28
Primary completion: 2025-02-13
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.